State Medicaid restrictions for DAA therapy do not impact post-transplant outcomes of recipients of HCV-viremic livers.

The introduction of direct-acting antivirals (DAA's) has coincided with a rise in the number of deceased donors infected with hepatitis C virus (HCV). As a result, there has been increased utilization of livers from HCV-viremic donors, both for HCV-negative patients (including those previously treated for HCV) as well as HCV-positive patients whose treatment is delayed until after transplant. The use of DAA's has resulted in similar post-transplant outcomes in recipients of HCV-viremic vs HCV-negative donors, regardless of the recipient's HCV status.1.